A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

被引：1
|
作者：
Liu, Wei [1 ]
Huang, Yunhong [2 ]
Yang, Haiyan [3 ]
Li, Zhiming [4 ]
Cai, Zhen [5 ]
Wang, Zhen [6 ]
Liu, Lihong [7 ]
Guo, Ye [8 ]
Liu, Ligen [9 ]
Huang, Rui [10 ]
Ye, Xu [11 ]
Qiu, Lugui [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp,Haihe Lab Cell Ecos, Tianjin, Peoples R China
[2] Guizhou Med Univ, Affiliated Canc Hosp, Guiyang, Peoples R China
[3] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[4] State Key Lab Oncol South China, Guangzhou, Peoples R China
[5] Zhejiang Univ, Sch Med, Bone Marrow Transplantat Ctr, Affiliated Hosp 1, Hangzhou, Peoples R China
[6] Linyi Canc Hosp, Linyi, Peoples R China
[7] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
[8] Shanghai East Hosp, Shanghai, Peoples R China
[9] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Shanghai, Peoples R China
[10] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China
[11] Guangzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Guangzhou, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-177550
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] A Phase I study evaluating AC676, an innovative BTK chimeric degrader, in patients with relapsed and refractory B-cell malignancies
    Woyach, Jennifer
    Tees, Michael
    Mota, Nancy
    Brown, Gladys
    Kim, Su Young
    Patel, Manish R.
    CANCER RESEARCH, 2024, 84 (07)
  • [32] Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
    Woyach, Jennifer
    Stephens, Deborah M.
    Flinn, Ian W.
    Bhat, Seema A.
    Savage, Ronald E.
    Chai, Feng
    Eathiraj, Sudharshan
    Granlund, Lindsey
    Szuszkiewicz, Lyndsey A.
    Schwartz, Brian
    Byrd, John C.
    BLOOD, 2019, 134
  • [33] A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
    Tuscano, Joseph M.
    Maverakis, Emanual
    Groshen, Susan
    Tsao-Wei, Denice
    Luxardi, Guillaume
    Merleev, Alexander A.
    Beaven, Anne
    DiPersio, John F.
    Popplewell, Leslie
    Chen, Robert
    Kirschbaum, Mark
    Schroeder, Mark A.
    Newman, Edward M.
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7004 - 7013
  • [34] Phase 1 clinical study ofAtacicept in patients with relapsed and refractory B-cell lymphoma.
    Ansell, Stephen
    Witzig, Thomas E.
    Novak, Anne
    Inwards, David James
    Porrata, Luis
    Ythier, A.
    Ferrande, L.
    Nestorov, I.
    DeVries, T.
    Sievers, Eric
    BLOOD, 2006, 108 (11) : 770A - 770A
  • [35] Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis
    Maerevoet, Marie
    Casasnovas, Olivier
    Cartron, Guillaume
    Morschhauser, Franck
    Thieblemont, Catherine
    Bouabdallah, Kamal
    Feugier, Pierre
    Szablewski, Vanessa
    Becker, Stephanie
    Tilly, Herve
    CANCERS, 2024, 16 (15)
  • [36] Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies
    Awan, Farrukh T.
    Gore, Lia
    Gao, Lei
    Sharma, Jyoti
    Lager, Joanne
    Costa, Luciano J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (01) : 55 - 65
  • [37] A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
    Samaniego, Felipe
    Sadiq, Ahad A.
    Mahadevan, Daruka
    Koontz, Michael Z.
    Villasboas, Jose C.
    Burke, John M.
    Reid, Erin G.
    Cherry, Mohamad
    Melear, Jason
    Priego, Victor
    Cobb, Patrick
    Cull, Elizabeth H.
    Conkling, Paul
    Cosgrove, David
    Roeker, Lindsey E.
    Haney, Donna Nguyen
    Hu, Jia
    Sinha, Ranjeet Kumar
    Rice, William G.
    Bejar, Rafael
    BLOOD, 2022, 140 : 6498 - 6500
  • [38] RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
    Lim, Sean H.
    Linton, Kim M.
    Collins, Graham P.
    Dhondt, Joke
    Caddy, Joshua
    Rossiter, Liz
    Vadher, Karan
    Fines, Keira
    Rogers, Laura E.
    Fernando, Diana
    Stanton, Louise
    Davies, Andrew J.
    Johnson, Peter W. M.
    Griffiths, Gareth
    TRIALS, 2018, 19
  • [39] RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
    Sean H. Lim
    Kim M. Linton
    Graham P. Collins
    Joke Dhondt
    Joshua Caddy
    Liz Rossiter
    Karan Vadher
    Keira Fines
    Laura E. Rogers
    Diana Fernando
    Louise Stanton
    Andrew J. Davies
    Peter W. M. Johnson
    Gareth Griffiths
    Trials, 19
  • [40] Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies
    Lyu, Jiaoyan
    Ma, Xiaopeng
    Huang, Ruiqi
    Zhao, Liyun
    Yu, Yiling
    Puig, Oscar
    Liu, Yang
    Hilger, James
    BLOOD, 2022, 140 : 3521 - 3522
12345